The firm said that its test is the first on the market to detect RSV infection at the point of care in 13 minutes or less.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
The real-time PCR-based test runs on the BD Max system and comes in a single tube that snaps into the BD MAX extraction cartridge.
The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
The École Polytechnique Fédérale de Lausanne's Samira Asgari uncovered rare variants that seem to govern an extreme response to RSV or HRV infection.
The test is the first of several planned CLIA-waived assays from Cepheid, and the first point-of-care test on the market to differentiate flu from RSV.
The Enigma MiniLab runs single-tube multiplex panels at the point of care, with a lower price point than other commercially available syndromic panel platforms.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.